DK1280540T3 - Modificeret faktor VIII - Google Patents

Modificeret faktor VIII

Info

Publication number
DK1280540T3
DK1280540T3 DK01910853T DK01910853T DK1280540T3 DK 1280540 T3 DK1280540 T3 DK 1280540T3 DK 01910853 T DK01910853 T DK 01910853T DK 01910853 T DK01910853 T DK 01910853T DK 1280540 T3 DK1280540 T3 DK 1280540T3
Authority
DK
Denmark
Prior art keywords
factor viii
modified factor
inhibitory antibodies
amino acid
modified
Prior art date
Application number
DK01910853T
Other languages
Danish (da)
English (en)
Inventor
John S Lollar
Original Assignee
Univ Emory
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Emory filed Critical Univ Emory
Application granted granted Critical
Publication of DK1280540T3 publication Critical patent/DK1280540T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/10—Factor VIII, AHF; related peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Glass Compositions (AREA)
  • Fish Paste Products (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
DK01910853T 2000-03-10 2001-02-16 Modificeret faktor VIII DK1280540T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/523,656 US6458563B1 (en) 1996-06-26 2000-03-10 Modified factor VIII
PCT/US2001/005076 WO2001068109A1 (en) 2000-03-10 2001-02-16 Modified factor viii

Publications (1)

Publication Number Publication Date
DK1280540T3 true DK1280540T3 (da) 2008-07-14

Family

ID=24085870

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01910853T DK1280540T3 (da) 2000-03-10 2001-02-16 Modificeret faktor VIII

Country Status (36)

Country Link
US (3) US6458563B1 (pt)
EP (1) EP1280540B1 (pt)
JP (1) JP4044337B2 (pt)
KR (1) KR100485525B1 (pt)
CN (1) CN1191360C (pt)
AT (1) ATE391512T1 (pt)
AU (2) AU2001238416B2 (pt)
BE (1) BE2016C024I2 (pt)
BR (2) BR122013026957A8 (pt)
CA (1) CA2400295C (pt)
CY (2) CY1108179T1 (pt)
CZ (1) CZ298250B6 (pt)
DE (1) DE60133541T2 (pt)
DK (1) DK1280540T3 (pt)
EE (1) EE05075B1 (pt)
ES (1) ES2304379T3 (pt)
FR (1) FR16C0016I2 (pt)
HK (1) HK1051004A1 (pt)
HU (2) HU227804B1 (pt)
IL (2) IL151371A0 (pt)
LT (1) LTC1280540I2 (pt)
LU (1) LU93049I2 (pt)
ME (1) MEP8209A (pt)
MX (1) MXPA02008798A (pt)
NL (1) NL300808I2 (pt)
NO (2) NO331935B1 (pt)
NZ (1) NZ520799A (pt)
PL (1) PL202936B1 (pt)
PT (1) PT1280540E (pt)
RS (1) RS50364B (pt)
RU (1) RU2285724C2 (pt)
SI (1) SI1280540T1 (pt)
SK (1) SK286205B6 (pt)
UA (1) UA75064C2 (pt)
WO (1) WO2001068109A1 (pt)
ZA (1) ZA200206810B (pt)

Families Citing this family (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7560107B2 (en) 1996-06-26 2009-07-14 Emory University Modified factor VIII
CA2434097A1 (en) * 2001-01-12 2002-08-08 The American National Red Cross Methods and compositions for reducing heparan sulfate proteoglycan-mediated clearance of factor viii
AU2002337901B2 (en) * 2001-10-05 2008-01-17 Expression Therapeutics Llc Nucleic acid and amino acid sequences encoding high-level expressor factor VIII polypeptides and methods of use
EP1456235A4 (en) * 2001-11-30 2005-08-17 Univ Emory VARIANTS OF DOMAIN C2 OF FACTOR VIII
GB0207092D0 (en) 2002-03-26 2002-05-08 Sod Conseils Rech Applic Stable pharmaceutical composition containing factor VIII
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
US7498024B2 (en) * 2003-06-03 2009-03-03 Cell Genesys, Inc. Compositions and methods for enhanced expression of immunoglobulins from a single vector using a peptide cleavage site
US7485291B2 (en) * 2003-06-03 2009-02-03 Cell Genesys, Inc. Compositions and methods for generating multiple polypeptides from a single vector using a virus derived peptide cleavage site, and uses thereof
ATE368687T1 (de) * 2003-06-26 2007-08-15 Merck Patent Gmbh Thrombopoietinproteine mit verbesserten eigenschaften
US20050059023A1 (en) * 2003-09-16 2005-03-17 Cantor Thomas L. Methods and kits for monitoring resistance to therapeutic agents
US7211559B2 (en) 2003-10-31 2007-05-01 University Of Maryland, Baltimore Factor VIII compositions and methods
WO2005055930A2 (en) * 2003-12-03 2005-06-23 University Of Rochester Recombinant factor viii having increased specific activity
PT1750733E (pt) 2004-05-03 2014-02-14 Baxter Healthcare Sa Método de administração de factor viii suíno sem domínio b
WO2005123928A1 (en) * 2004-06-08 2005-12-29 Battelle Memorial Institute Production of human coagulation factor viii from plant cells and whole plants
HUE050542T2 (hu) * 2004-11-12 2020-12-28 Bayer Healthcare Llc FVIII helyspecifikus módosítása
US20100256062A1 (en) * 2004-12-06 2010-10-07 Howard Tommy E Allelic Variants of Human Factor VIII
US7855279B2 (en) 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
EP1968999A2 (en) 2005-12-07 2008-09-17 Technische Universität München Small peptidic and peptido-mimetic affinity ligands for factor viii and factor viii-like proteins
EP1816201A1 (en) 2006-02-06 2007-08-08 CSL Behring GmbH Modified coagulation factor VIIa with extended half-life
JP2009533364A (ja) * 2006-04-11 2009-09-17 ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー 治療用ポリペプチドのインビボでの回収を増大させる方法
US7939632B2 (en) * 2006-06-14 2011-05-10 Csl Behring Gmbh Proteolytically cleavable fusion proteins with high molar specific activity
EP1935430A1 (en) * 2006-12-22 2008-06-25 CSL Behring GmbH Modified coagulation factors with prolonged in vivo half-life
CA2673459C (en) 2006-12-22 2016-09-13 Stefan Schulte Modified coagulation factors with prolonged in vivo half-life
FR2913020B1 (fr) * 2007-02-23 2012-11-23 Biomethodes Nouveaux facteurs viii pour le traitement des hemophiles de type a
EP1988101A1 (en) 2007-05-04 2008-11-05 Novo Nordisk A/S Improvement of factor VIII polypeptide titers in cell cultures
US8338571B2 (en) 2007-11-01 2012-12-25 University Of Rochester Recombinant factor VIII having increased stability
EP2149603A1 (en) 2008-07-28 2010-02-03 DRK-Blutspendedienst Baden-Württemberg-Hessen gGmbH Factor IX variants with clotting activity in absence of their cofactor and their use for treating bleeding disorders
EP2393828B1 (en) 2009-02-03 2016-10-12 Amunix Operating Inc. Extended recombinant polypeptides and compositions comprising same
PT2440239T (pt) 2009-06-09 2017-10-19 Prolong Pharmaceuticals Llc Composições de hemoglobina
JP5813641B2 (ja) 2009-08-24 2015-11-17 アムニクス オペレーティング インコーポレイテッド 凝固第ｉｘ因子組成物ならびにそれを製造および使用する方法
EP2742949A1 (en) * 2009-11-13 2014-06-18 Puget Sound Blood Center Factor VIII B cell epitope variants having reduced immunogenicity
SG10201907152YA (en) 2009-12-06 2019-09-27 Bioverativ Therapeutics Inc Factor viii-fc chimeric and hybrid polypeptides, and methods of use thereof
EP2524054A2 (en) * 2010-01-14 2012-11-21 Haplomics, Inc. Predicting and reducing alloimmunogenicity of protein therapeutics
EP2591099B1 (en) 2010-07-09 2020-11-18 Bioverativ Therapeutics Inc. Chimeric clotting factors
WO2012006623A1 (en) 2010-07-09 2012-01-12 Biogen Idec Hemophilia Inc. Systems for factor viii processing and methods thereof
US9150637B2 (en) 2010-11-05 2015-10-06 Baxalta Inc. Variant of antihemophilic factor VIII having increased specific activity
JP2014504870A (ja) * 2011-01-05 2014-02-27 エクスプレッション セラピューティクス， エルエルシー 高収率懸濁細胞株、システム、およびその製造方法
PT2717898T (pt) 2011-06-10 2019-05-20 Bioverativ Therapeutics Inc Compostos pró-coagulantes e processos para a sua utilização
AU2012282875B2 (en) 2011-07-08 2016-04-21 Bioverativ Therapeutics Inc. Factor VIII chimeric and hybrid polypeptides, and methods of use thereof
EA028914B1 (ru) 2011-07-25 2018-01-31 Байоджен Хемофилия Инк. Исследования для мониторинга нарушений свертываемости крови
CN102277379B (zh) * 2011-08-18 2013-07-24 中国科学院遗传与发育生物学研究所 表达凝血因子viii的表达载体及其应用
MY201293A (en) 2012-01-12 2024-02-15 Bioverativ Therapeutics Inc Chimeric factor viii polypeptides and uses thereof
LT2802668T (lt) 2012-01-12 2018-11-26 Bioverativ Therapeutics Inc. Imunogeninio atsako prieš faktorių viii individuose, kuriems skiriama faktoriaus viii terapija, sumažinimas
AU2013204636B2 (en) 2012-02-15 2016-04-14 Bioverativ Therapeutics Inc. Recombinant Factor VIII proteins
CA2864904C (en) 2012-02-15 2023-04-25 Amunix Operating Inc. Factor viii compositions and methods of making and using same
EP2666782A1 (en) * 2012-05-22 2013-11-27 Imnate Sarl Coagulation factor VIII with reduced immunogenicity.
WO2013185114A2 (en) 2012-06-08 2013-12-12 Biogen Idec Ma Inc. Chimeric clotting factors
EP4079316A1 (en) 2012-06-08 2022-10-26 Bioverativ Therapeutics Inc. Procoagulant compounds
WO2014008480A2 (en) 2012-07-06 2014-01-09 Biogen Idec Ma Inc. Cell line expressing single chain factor viii polypeptides and uses thereof
PL2882450T3 (pl) 2012-07-11 2020-06-29 Bioverativ Therapeutics Inc. Kompleks czynnika viii z xten i białkiem czynnika von willebranda oraz jego zastosowania
EP2877202A4 (en) 2012-07-25 2016-06-01 Biogen Ma Inc BLOOD FACTOR MONITORING TEST AND USES THEREOF
WO2014063108A1 (en) 2012-10-18 2014-04-24 Biogen Idec Ma Inc. Methods of using a fixed dose of a clotting factor
EP3943102A1 (en) 2012-10-30 2022-01-26 Bioverativ Therapeutics Inc. Methods of using fviii polypeptide
US10272163B2 (en) 2012-12-07 2019-04-30 The Regents Of The University Of California Factor VIII mutation repair and tolerance induction
WO2014127215A1 (en) 2013-02-15 2014-08-21 Biogen Idec Ma Inc. Optimized factor viii gene
TWI828269B (zh) 2013-03-15 2024-01-01 美商百歐維拉提夫治療公司 因子ix多肽調配物
EA201890671A1 (ru) 2013-03-15 2019-01-31 Биовератив Терапьютикс Инк. Препараты полипептида фактора viii
CN105392495A (zh) 2013-06-28 2016-03-09 比奥根Ma公司 具有xten的凝血酶可裂解连接子和其用途
WO2015021423A2 (en) 2013-08-08 2015-02-12 Biogen Idec Ma Inc. Purification of chimeric fviii molecules
US10548953B2 (en) 2013-08-14 2020-02-04 Bioverativ Therapeutics Inc. Factor VIII-XTEN fusions and uses thereof
CN105848670A (zh) 2013-10-22 2016-08-10 Dbv技术公司 通过诱导对血液因子的耐受治疗血友病的方法
US10584147B2 (en) 2013-11-08 2020-03-10 Biovertiv Therapeutics Inc. Procoagulant fusion compound
EP3082848B1 (en) 2013-12-06 2023-10-18 Bioverativ Therapeutics Inc. Population pharmacokinetics tools and uses thereof
EP2881463A1 (en) 2013-12-09 2015-06-10 DRK-Blutspendedienst Baden-Württemberg-Hessen gGmbH Factor IX variants with clotting activity in absence of their cofactor and/or with increased F.IX clotting activity and their use for treating bleeding disorders
PT4176894T (pt) 2014-01-10 2024-05-21 Bioverativ Therapeutics Inc Proteínas quiméricas de fator viii e utilizações destas
EP3102589A1 (en) 2014-02-04 2016-12-14 Biogen MA Inc. Use of cation-exchange chromatography in the flow-through mode to enrich post-translational modifications
WO2015127129A1 (en) * 2014-02-19 2015-08-27 Bloodworks Factor viii b cell epitope variants having reduced immunogenicity
WO2015132724A1 (en) 2014-03-05 2015-09-11 Pfizer Inc. Improved muteins of clotting factor viii
MA40864A (fr) 2014-10-31 2017-09-05 Biogen Ma Inc Hypotaurine, gaba, bêta-alanine et choline pour la régulation de l'accumulation de sous-produits résiduaires dans des procédés de culture de cellules mammifères
EP3331608A4 (en) 2015-08-03 2019-05-01 Bioverativ Therapeutics Inc. FUSION XI FUSION PROTEINS AND METHODS OF MAKING AND USING THE SAME
PE20231949A1 (es) * 2015-10-30 2023-12-05 Spark Therapeutics Inc VARIANTES DEL FACTOR VIII REDUCIDO CON CpG, COMPOSICIONES Y METODOS Y USOS PARA EL TRATAMIENTO DE TRASTORNOS DE LA HEMOSTASIA
CN116479001A (zh) 2015-11-13 2023-07-25 武田药品工业株式会社 用于血友病a的基因治疗的具有增加的表达的编码重组fviii变体的病毒载体
TWI823830B (zh) 2015-11-13 2023-12-01 日商武田藥品工業股份有限公司 用於ａ型血友病基因治療之編碼表現增加之重組ｆｖｉｉｉ變異體之病毒載體
SI3411478T1 (sl) 2016-02-01 2022-10-28 Bioverativ Therapeutics Inc. Optimirani geni dejavnika VIII
KR102175878B1 (ko) 2016-06-24 2020-11-06 재단법인 목암생명과학연구소 Fviii 및 vwf 인자를 포함하는 키메라 단백질 및 그 용도
MX2019006446A (es) 2016-12-02 2019-12-11 Bioverativ Therapeutics Inc Métodos para inducir tolerancia inmunológica a factores de coagulación.
WO2018102743A1 (en) 2016-12-02 2018-06-07 Bioverativ Therapeutics Inc. Methods of treating hemophilic arthropathy using chimeric clotting factors
EP3622065A1 (en) * 2017-05-09 2020-03-18 Emory University Clotting factor variants and their use
KR20200035130A (ko) 2017-08-09 2020-04-01 바이오버라티브 테라퓨틱스 인크. 핵산 분자 및 이의 용도
CN111918674A (zh) 2018-02-01 2020-11-10 比奥维拉迪维治疗股份有限公司 表达因子viii的慢病毒载体的用途
JP2021520374A (ja) 2018-04-04 2021-08-19 シギロン セラピューティクス， インコーポレイテッドＳｉｇｉｌｏｎ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． 移植可能な粒子及び関連方法
US12030925B2 (en) 2018-05-18 2024-07-09 Bioverativ Therapeutics Inc. Methods of treating hemophilia A
US20220333135A1 (en) 2018-07-16 2022-10-20 Baxalta Incorporated Gene therapy of hemophilia a using viral vectors encoding recombinant fviii variants with increased expression
BR112021002017A2 (pt) 2018-08-09 2021-05-11 Bioverativ Therapeutics Inc. moléculas de ácido nucleico e usos das mesmas para terapia genética não viral
UY38389A (es) 2018-09-27 2020-04-30 Sigilon Therapeutics Inc Dispositivos implantables para terapia celular y métodos relacionados
TW202039546A (zh) 2019-01-16 2020-11-01 美商巴克斯歐塔公司 用於a型血友病基因治療之編碼表現增加之重組fviii變異體的病毒載體
JP2022537200A (ja) 2019-06-19 2022-08-24 バイオベラティブ セラピューティクス インコーポレイテッド 血友病および低骨ミネラル密度を処置するための方法および組成物
JP2022537555A (ja) 2019-06-20 2022-08-26 武田薬品工業株式会社 ウイルスベースの遺伝子療法による治療方法
WO2021119357A2 (en) 2019-12-12 2021-06-17 Baxalta Incorporated Gene therapy of hemophilia a using viral vectors encoding recombinant fviii variants with increased expression
TW202246505A (zh) * 2021-03-05 2022-12-01 俄羅斯聯邦商亞那拜恩有限公司 編碼凝血因子ｉｘ蛋白的密碼子優化的核酸及其用途
EP4314819A1 (en) 2021-03-31 2024-02-07 Haemonetics Corporation Hemostasis measurement device quality control formulations
EP4355768A1 (en) 2021-06-14 2024-04-24 Takeda Pharmaceutical Company Limited Gene therapy of hemophilia a using viral vectors encoding recombinant fviii variants with increased expression
TW202323274A (zh) 2021-08-23 2023-06-16 美商百歐維拉提夫治療公司 優化因子viii基因
AU2022355088A1 (en) 2021-09-30 2024-05-16 Bioverativ Therapeutics Inc. Nucleic acids encoding factor viii polypeptides with reduced immunogenicity
WO2024081309A1 (en) 2022-10-11 2024-04-18 Sigilon Therapeutics, Inc. Engineered cells and implantable elements for treatment of disease

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4757006A (en) 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
EP0182448A3 (en) 1984-08-24 1987-10-28 Genetics Institute, Inc. Production of factor viii and related products
CA1341174C (en) 1985-04-12 2001-01-30 John J. Toole Jr. Procoagulant proteins derived from factor viii: c
JPH0387173A (ja) 1987-09-10 1991-04-11 Teijin Ltd ヒト活性化天然型ファクター８ｃの製造方法及びそれに用いる形質転換体
DK162233C (da) 1989-11-09 1992-03-16 Novo Nordisk As Fremgangsmaade til isolering af faktor viii fra blodplasma og pharmaceutisk praeparat indeholdende den saaledes isolerede fator viii
US6180371B1 (en) * 1996-06-26 2001-01-30 Emory University Modified factor VIII
US5364771A (en) 1992-04-07 1994-11-15 Emory University Hybrid human/porcine factor VIII
US5663060A (en) 1992-04-07 1997-09-02 Emory University Hybrid human/animal factor VIII
US5563045A (en) 1992-11-13 1996-10-08 Genetics Institute, Inc. Chimeric procoagulant proteins
AU6455896A (en) 1995-07-11 1997-02-10 Chiron Corporation Novel factor viii:c polypeptide analogs with altered metal-binding properties
AU6291896A (en) 1995-07-11 1997-02-10 Chiron Corporation Novel factor viii:c polypeptide analogs comprising factor v domains or subdomains
EP1319016A4 (en) * 2000-09-19 2006-05-10 Univ Emory MODIFIED FACTOR VIII
EP1456235A4 (en) * 2001-11-30 2005-08-17 Univ Emory VARIANTS OF DOMAIN C2 OF FACTOR VIII
US7105745B2 (en) * 2002-12-31 2006-09-12 Thomas & Betts International, Inc. Water resistant electrical floor box cover assembly

Also Published As

Publication number Publication date
US7012132B2 (en) 2006-03-14
KR20020081426A (ko) 2002-10-26
US6458563B1 (en) 2002-10-01
EE200200510A (et) 2004-02-16
BRPI0109131B8 (pt) 2021-07-06
LU93049I2 (fr) 2016-06-27
NO2016007I1 (no) 2016-05-10
WO2001068109A1 (en) 2001-09-20
NZ520799A (en) 2004-06-25
AU2001238416B2 (en) 2004-09-02
JP4044337B2 (ja) 2008-02-06
US20050079584A1 (en) 2005-04-14
ZA200206810B (en) 2003-11-26
ES2304379T3 (es) 2008-10-16
EE05075B1 (et) 2008-10-15
HU227804B1 (en) 2012-03-28
BR0109131A (pt) 2004-12-07
CN1191360C (zh) 2005-03-02
ME00601B (me) 2011-12-20
FR16C0016I2 (fr) 2018-11-02
BR122013026957A8 (pt) 2017-02-21
PL359672A1 (en) 2004-09-06
SK286205B6 (sk) 2008-05-06
NO331935B1 (no) 2012-05-07
KR100485525B1 (ko) 2005-04-28
NO20024296L (no) 2002-11-08
RU2002124123A (ru) 2004-03-27
CY1108179T1 (el) 2014-02-12
PT1280540E (pt) 2008-06-09
NL300808I1 (pt) 2016-05-18
DE60133541T2 (de) 2009-05-07
HUP0300586A3 (en) 2006-11-28
US20030068785A1 (en) 2003-04-10
SI1280540T1 (sl) 2008-08-31
RS50364B (sr) 2009-11-10
CN1416348A (zh) 2003-05-07
ATE391512T1 (de) 2008-04-15
DE60133541D1 (de) 2008-05-21
BR122013026957A2 (pt) 2004-12-07
EP1280540B1 (en) 2008-04-09
MXPA02008798A (es) 2003-04-25
BE2016C024I2 (pt) 2020-01-30
IL151371A (en) 2010-12-30
HUS1600020I1 (hu) 2016-06-28
EP1280540A4 (en) 2004-11-03
HUP0300586A2 (hu) 2003-06-28
JP2003526358A (ja) 2003-09-09
FR16C0016I1 (pt) 2016-04-29
US7122634B2 (en) 2006-10-17
MEP8209A (en) 2011-12-20
CA2400295A1 (en) 2001-09-20
CZ20023346A3 (cs) 2003-01-15
EP1280540A1 (en) 2003-02-05
CY2016011I2 (el) 2016-10-05
UA75064C2 (en) 2006-03-15
LTC1280540I2 (lt) 2020-05-25
SK14392002A3 (sk) 2003-06-03
CZ298250B6 (cs) 2007-08-01
NL300808I2 (nl) 2020-12-21
CY2016011I1 (el) 2016-10-05
YU68002A (sh) 2005-11-28
NO20024296D0 (no) 2002-09-09
RU2285724C2 (ru) 2006-10-20
BRPI0109131B1 (pt) 2020-08-25
IL151371A0 (en) 2003-04-10
NO2016007I2 (no) 2016-05-10
HK1051004A1 (en) 2003-07-18
PL202936B1 (pl) 2009-08-31
CA2400295C (en) 2012-01-10
AU3841601A (en) 2001-09-24

Similar Documents

Publication Publication Date Title
NO2016007I2 (no) Susoktokog
DE60019122D1 (de) Veränderter faktor viii
HUP0301179A2 (hu) Módosított VIII-as faktor
DK1200418T3 (da) Nematodicide trifluorbutener
ATE250605T1 (de) Piperidin verbindung zur behandlung von psoriasis
DE60101265D1 (de) Behandlung von augenschmerzen
MXPA04005079A (es) Variantes del dominio c2 del factor viii.
ATE389395T1 (de) Substituierte 2-aminotetraline zur vorbeugenden behandlung von morbus parkinson
NO20025405D0 (no) Modulatorer for TNF-alfa-signalisering
CY1105317T1 (el) Χρηση υποκατεστημενων ενωσεων 6-διμεθυλαμινομεθυλο-1-φαινυλο-κυκλοεξανιου για τη θepαπεια της ακρατειας ουρων
CY1105142T1 (el) Χρηση υποκατεστημενων ενωσεων 6-διμεθυλαμινομεθυλο-1-φαινυλο-κυκλοεξανιου για τη θepαπεια της ακρατειας ουρων
DE60036122D1 (de) Verwendung von eplerenon zur behandlung von restenose
DE60142786D1 (de) Zusammensetzungen und methoden zur behandlung von candidosen
ATE274513T1 (de) Verbindungen und verfahren zur behandlung von schmerz
DE60313005D1 (de) Behandlung von dyskinesie mit 2,3-benzodiazepinen
DE50000676D1 (de) Verwendung von orosomucoid zur herstellung einer pharmazeutischen präparation zur behandlung von pankreatitis